Back to Search Results

The Effect of Far-Infrared Therapy on the Peritoneal Expression of Glucose Degradation Products in Diabetic Patients on Peritoneal Dialysis.

Institute of Food Safety and Health Risk Assessment, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan. Institute of Food Safety and Health Risk Assessment, National Yang-Ming University, Taipei 112, Taiwan. Department of Pharmacy, National Taiwan University Hospital, Taipei 100, Taiwan. School of Medicine, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan. School of Medicine, National Yang-Ming University, Taipei 112, Taiwan. Department of Medicine, Division of Nephrology, Taipei Veterans General Hospital, Taipei 112, Taiwan. Department of Internal Medicine, Division of Nephrology, National Yang Ming Chiao Tung University Hospital, Yilan 260, Taiwan. Department of Medicine, Division of Nephrology, Taipei Veterans General Hospital Fenglin Branch, Hualien 975, Taiwan. Department of Internal Medicine, Division of Nephrology, Taipei City Hospital Heping Fuyou Branch, Taipei 100, Taiwan. Center for General Education, National Taipei University, Taipei 104, Taiwan. Department of Medicine, Division of Nephrology, Taipei City Hospital Zhongxing Branch, Taipei 103, Taiwan. Metabolomics-Proteomics Research Center, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.

International journal of molecular sciences. 2021;(7)
Full text from:

Other resources

Abstract

Peritoneal dialysis (PD) is a treatment modality for end-stage renal disease (ESRD) patients. Dextrose is a common osmotic agent used in PD solutions and its absorption may exacerbate diabetes mellitus, a common complication of ESRD. PD solutions also contain glucose degradation products (GDPs) that may lead to encapsulating peritoneal sclerosis (EPS), a severe complication of PD. A previous study showed that far-infrared (FIR) therapy improved a patient's gastrointestinal symptoms due to EPS. Due to limited literature on the matter, this study aims to investigate dialysate GDPs and peritoneal function in diabetic patients on PD. Thirty-one PD patients were enrolled and underwent 40 min of FIR therapy twice daily for six months. We demonstrated the effect of FIR therapy on the following: (1) decrease of methylglyoxal (p = 0.02), furfural (p = 0.005), and 5-hydroxymethylfurfural (p = 0.03), (2) increase of D/D0 glucose ratio (p = 0.03), and (3) decrease of potassium levels (p = 0.008) in both DM and non-DM patients, as well as (4) maintenance and increase of peritoneal Kt/V in DM and non-DM patients, respectively (p = 0.03). FIR therapy is a non-invasive intervention that can decrease dialysate GDPs in PD patients by improving peritoneal transport rate and solute removal clearance, while also maintaining dialysis adequacy.

Methodological quality

Publication Type : Clinical Trial

Metadata